Myeloma Treatment Landscape Continues to ChangeJune 2nd 2019
Monoclonal antibodies, proteasome inhibitors, and targeted agents are among the many options in the crowded treatment landscape of relapsed/refractory multiple myeloma, and the emergence of drugs, such as venetoclax (Venclexta) and selinexor, could add to the complexity of this paradigm, said Cristina Gasparetto, MD.
Pembrolizumab's Journey to the Frontline in NSCLCNovember 26th 2018
The PD-1 inhibitor pembrolizumab (Keytruda) has shown an overall survival advantage across 3 phase III clinical trials studying its use in patients with metastatic non–small cell lung cancer (NSCLC). These positive results led to a frontline indication as a single agent and in combination with chemotherapy for both patients with squamous and nonsquamous NSCLC.
Exploring the Global Impact of Biosimilars in Cancer TreatmentAugust 31st 2018
As the cost of cancer therapies continues to increase, the cancer community is looking to biosimilars as a potential alternative for treatment; however, experts wonder if factors besides cost need to be taken in to consideration.